Patents by Inventor Lee Brettman

Lee Brettman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080085916
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: December 7, 2007
    Publication date: April 10, 2008
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Fraser, Karl Thor, Edward Burgard, Lee Brettman, Steven Landau, Daniel Ricca
  • Publication number: 20070060652
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: November 13, 2006
    Publication date: March 15, 2007
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Fraser, Karl Thor, Edward Burgard, Lee Brettman, Steven Landau, Daniel Ricca
  • Publication number: 20060276542
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: March 22, 2004
    Publication date: December 7, 2006
    Inventors: Matthew Fraser, Karl Thor, Edward Burgard, Lee Brettman, Steven Landau, Daniel Ricca
  • Publication number: 20060264509
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: March 22, 2004
    Publication date: November 23, 2006
    Inventors: Matthew Fraser, Karl Thor, Edward Burgard, Lee Brettman, Steven Landau, Daniel Ricca
  • Publication number: 20060247311
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: April 7, 2006
    Publication date: November 2, 2006
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Fraser, Karl Thor, Edward Burgard, Lee Brettman, Steven Landau, Daniel Ricca
  • Publication number: 20050239890
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: May 10, 2005
    Publication date: October 27, 2005
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Fraser, Karl Thor, Edward Burgard, Lee Brettman, Steven Landau, Daniel Ricca
  • Publication number: 20050095238
    Abstract: Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.
    Type: Application
    Filed: December 15, 2003
    Publication date: May 5, 2005
    Applicants: Millennium Pharmaceuticals, Inc., Genentech, Inc.
    Inventors: Lee Brettman, Judith Fox, David Allison